Exelixis Q2 Earnings Fall Short, Shares Bounce Back
In its Q2 2026 financial report, biopharmaceutical company Exelixis missed revenue expectations as sales of its flagship cancer drug Cabometyx came in about $17 million below forecasts. Additionally, revenue from its thyroid cancer treatment Cometriq was approximately $500,000 short of estimates. Following the earnings release, Exelixis shares dropped nearly 8%, but later rebounded sharply, breaking above the technical buy point at $57.57 and reaching a buying range near $60.45, signaling renewed investor interest.
Zanzalintinib FDA Approval Expected By December
Exelixis is banking on its next-generation oncology drug, Zanzalintinib, to drive future growth. The drug is in late-stage clinical trials and is anticipated to receive U.S. FDA approval as early as December 3, targeting patients with previously treated metastatic colorectal cancer. The company also plans to release new clinical data related to non-clear cell renal cell carcinoma—one of the common kidney cancer subtypes—later this year. Analysts estimate that Zanzalintinib could generate initial market opportunities worth approximately $700 million, although competitive pressures remain a concern.
Market Focus on Transition From Cabometyx to New Therapies
A key analyst focus is whether Exelixis can successfully transition from its current tyrosine kinase inhibitor, Cabometyx, to Zanzalintinib. While Cabometyx’s sales growth in neuroendocrine tumors has slowed, it continues to maintain a leading position among kidney cancer treatments. RBC Capital Markets analyst Leonid Timashev sees potential total sales of up to $1.4 billion across colorectal, kidney, and neuroendocrine cancers for Zanzalintinib but notes short-term uncertainties pending further clinical validation. Leerink Partners’ Andrew Berens acknowledges that the market expectations for Zanzalintinib are largely priced into current stock levels and has moderated his rating to market perform, highlighting cautious sentiment for 2027 and beyond.
Technical Strength and Market Position
Technically, Exelixis has demonstrated resilience, ranking in the top 9% of stock performance over the past year with an IBD composite rating of 99, placing it in the top 1% of its sector. It is listed 28th on the IBD 50 growth stock leaderboard, reflecting sustained market confidence in its long-term prospects. Although the company adjusted its full-year revenue guidance downward by $50 million, investors remain attentive to the progress of Zanzalintinib’s approval and upcoming clinical data releases, which will be key drivers of Exelixis’ valuation and competitive positioning going forward.